Top

Published in:

22-11-2023 | Neuroendocrine Tumor

The Quest for Circulating Biomarkers in Neuroendocrine Neoplasms: a Clinical Perspective

Authors: Laura Mariën, MSc, Odeta Islam, MD, Siddharth Chhajlani, MD, Willem Lybaert, MD, Marc Peeters, MD, PhD, Guy Van Camp, PhD, Ken Op de Beeck, PhD, Timon Vandamme, MD, PhD

Published in: Current Treatment Options in Oncology | Issue 12/2023

Opinion statement

Given the considerable heterogeneity in neuroendocrine neoplasms (NENs), it appears unlikely that a sole biomarker exists capable of fully capturing all useful clinical aspects of these tumors. This is reflected in the abundant number of biomarkers presently available for the diagnosis, prognosis, and monitoring of NEN patients. Although assessment of immunohistochemical and radiological markers remains paramount and often obligatory, there has been a notable surge of interest in circulating biomarkers over the years given the numerous benefits associated with liquid biopsies. Currently, the clinic primarily relies on single-analyte assays such as the chromogranin A assay, but these are far from ideal because of limitations such as compromised sensitivity and specificity as well as a lack of standardization. Consequently, the quest for NEN biomarkers continued with the exploration of multianalyte markers, exemplified by the development of the NETest and ctDNA-based analysis. Here, an extensive panel of markers is simultaneously evaluated to identify distinct signatures that could enhance the accuracy of patient diagnosis, prognosis determination, and response to therapy prediction and monitoring. Given the promising results, the development and implementation of these multianalyte markers are expected to usher in a new era of NEN biomarkers in the clinic. In this review, we will outline both clinically implemented and more experimental circulating markers to provide an update on developments in this rapidly evolving field.

Rizen EN, Phan AT. Neuroendocrine tumors: a relevant clinical update. Curr Oncol Rep. 2022;24(6):703–14. https://doi.org/10.1007/s11912-022-01217-z.CrossRefPubMed

Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42. https://doi.org/10.1001/jamaoncol.2017.0589.CrossRefPubMedPubMedCentral

Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia (New York, NY). 2017;19(12):991–1002. https://doi.org/10.1016/j.neo.2017.09.002.CrossRef

Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (New York, NY). 2011;331(6021):1199–203. https://doi.org/10.1126/science.1200609.CrossRef

Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115–54. https://doi.org/10.1007/s12022-022-09708-2.CrossRefPubMed

Aluri V, Dillon JS. Biochemical testing in neuroendocrine tumors. Endocrinol Metab Clin N Am. 2017;46(3):669–77. https://doi.org/10.1016/j.ecl.2017.04.004.CrossRef

Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, et al. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16(9):e435–46. https://doi.org/10.1016/s1470-2045(15)00186-2.CrossRefPubMedPubMedCentral

Ciobanu OA, Martin S, Fica S. Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review). Exp Ther Med. 2021;22(6):1479. https://doi.org/10.3892/etm.2021.10914.CrossRefPubMedPubMedCentral

Herrera-Martínez AD, Hofland LJ, Gálvez Moreno MA, Castaño JP, de Herder WW, Feelders RA. Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. Endocr Relat Cancer. 2019;26(3):R157-r79. https://doi.org/10.1530/erc-18-0354.CrossRefPubMed

10.

Modlin IM, Kidd M, Malczewska A, Drozdov I, Bodei L, Matar S, et al. The NETest: the clinical utility of multigene blood analysis in the diagnosis and management of neuroendocrine tumors. Endocr Metab Clin N Am. 2018;47(3):485–504. https://doi.org/10.1016/j.ecl.2018.05.002.CrossRef

11.

Malczewska A, Kos-Kudła B, Kidd M, Drozdov I, Bodei L, Matar S, et al. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors. Adv Med Sci. 2020;65(1):18–29. https://doi.org/10.1016/j.advms.2019.10.002.CrossRefPubMed

12.

• Boons G, Vandamme T, Mariën L, Lybaert W, Roeyen G, Rondou T, et al. Longitudinal copy-number alteration analysis in plasma cell-free DNA of neuroendocrine neoplasms is a novel specific biomarker for diagnosis, prognosis, and follow-up. Cli Cancer Res. 2022;28(2):338–49. https://doi.org/10.1158/1078-0432.ccr-21-2291. This paper reveals that the CNA patterns in the cfDNA of NEN patients could serve as a novel, highly specific biomarker.CrossRef

13.

Marotta V, Zatelli MC, Sciammarella C, Ambrosio MR, Bondanelli M, Colao A, et al. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocri Relat Cancer. 2018;25(1):R11-r29. https://doi.org/10.1530/erc-17-0269.CrossRef

14.

Matar S, Malczewska A, Oberg K, Bodei L, Aslanian H, Lewczuk-Myślicka A, et al. Blood chromogranin A is not effective as a biomarker for diagnosis or management of bronchopulmonary neuroendocrine tumors/neoplasms. Neuroendocrinology. 2020;110(3–4):185–97. https://doi.org/10.1159/000500202.CrossRefPubMed

15.

Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86(5):858–65. https://doi.org/10.1002/(sici)1097-0142(19990901)86:5%3c858::aid-cncr23%3e3.0.co;2-8.CrossRefPubMed

16.

Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab. 1997;82(8):2622–8. https://doi.org/10.1210/jcem.82.8.4145.CrossRefPubMed

17.

Baudin E, Gigliotti A, Ducreux M, Ropers J, Comoy E, Sabourin JC, et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer. 1998;78(8):1102–7. https://doi.org/10.1038/bjc.1998.635.CrossRefPubMedPubMedCentral

18.

Panzuto F, Severi C, Cannizzaro R, Falconi M, Angeletti S, Pasquali A, et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest. 2004;27(1):6–11. https://doi.org/10.1007/bf03350903.CrossRefPubMed

19.

Walter T, Chardon L, Chopin-laly X, Raverot V, Caffin AG, Chayvialle JA, et al. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours? Eur J Cancer (Oxford, England : 1990). 2012;48(12):1766–73. https://doi.org/10.1016/j.ejca.2011.11.005.

20.

Chauhan A, Prieur A, Kolesar J, Arnold S, Payen L, Mahi Y, et al. hPG(80) (circulating progastrin), a novel blood-based biomarker for detection of poorly differentiated neuroendocrine carcinoma and well differentiated neuroendocrine tumors. Cancers. 2022;14(4). https://doi.org/10.3390/cancers14040863.

21.

Öberg K, Califano A, Strosberg JR, Ma S, Pape U, Bodei L, et al. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Ann Oncol. 2020;31(2):202–12. https://doi.org/10.1016/j.annonc.2019.11.003.CrossRefPubMed

22.

Fang JM, Li J, Shi J. An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. World J Gastroenterol. 2022;28(10):1009–23. https://doi.org/10.3748/wjg.v28.i10.1009.CrossRefPubMedPubMedCentral

23.

Rizzo FM, Meyer T. Liquid biopsies for neuroendocrine tumors: circulating tumor cells, DNA, and microRNAs. Endocr Metab Clin N Am. 2018;47(3):471–83. https://doi.org/10.1016/j.ecl.2018.04.002.CrossRef

24.

Mader S, Pantel K. Liquid biopsy: current status and future perspectives. Oncol Res Treat. 2017;40(7–8):404–8. https://doi.org/10.1159/000478018.CrossRefPubMed

25.

Hofland J, Zandee WT, de Herder WW. Role of biomarker tests for diagnosis of neuroendocrine tumours. Nat Rev Endocrinol. 2018;14(11):656–69. https://doi.org/10.1038/s41574-018-0082-5.CrossRefPubMed

26.

Kanakis G, Kaltsas G. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract Res Clin Gastroenterol. 2012;26(6):791–802. https://doi.org/10.1016/j.bpg.2012.12.006.CrossRefPubMed

27.

Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT, et al. ENETS consensus guidelines for standard of care in neuroendocrine tumours: biochemical markers. Neuroendocrinology. 2017;105(3):201–11. https://doi.org/10.1159/000472254.CrossRefPubMed

28.

Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology. 2016;103(2):125–38. https://doi.org/10.1159/000443170.CrossRefPubMed

29.

Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas. 2010;39(6):753–66. https://doi.org/10.1097/MPA.0b013e3181ebb2a5.CrossRefPubMed

30.

Rehfeld JF, Broedbaek K, Goetze JP, Knigge U, Hilsted LM. True chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours. Scand J Gastroenterol. 2020;55(5):565–73. https://doi.org/10.1080/00365521.2020.1759141.CrossRefPubMed

31.

Erickson JA, Chiang FI, Walker CM, Genzen JR, Doyle K. Comparison of two chromogranin A assays and investigation of nonlinear specimens. Pract Lab Med. 2022;32: e00299. https://doi.org/10.1016/j.plabm.2022.e00299.CrossRefPubMedPubMedCentral

32.

Modlin IM, Oberg K, Taylor A, Drozdov I, Bodei L, Kidd M. Neuroendocrine tumor biomarkers: current status and perspectives. Neuroendocrinology. 2014;100(4):265–77. https://doi.org/10.1159/000368363.CrossRefPubMed

33.

Hofland J, Kaltsas G, de Herder WW. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr Rev. 2020;41(2):371–403. https://doi.org/10.1210/endrev/bnz004.CrossRefPubMedPubMedCentral

34.

Roll W, Weckesser M, Seifert R, Bodei L, Rahbar K. Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management. Eur J Nucl Med Mol Imaging. 2021;48(12):4016–27. https://doi.org/10.1007/s00259-021-05359-3.CrossRefPubMedPubMedCentral

35.

Massironi S, Rossi RE, Casazza G, Conte D, Ciafardini C, Galeazzi M, et al. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution. Neuroendocrinology. 2014;100(2–3):240–9. https://doi.org/10.1159/000369818.CrossRefPubMed

36.

Krogh S, Grønbæk H, Knudsen AR, Kissmeyer-Nielsen P, Hummelshøj NE, Dam G. Predicting progression, recurrence, and survival in pancreatic neuroendocrine tumors: a single center analysis of 174 patients. Front Endocrinol. 2022;13: 925632. https://doi.org/10.3389/fendo.2022.925632.CrossRef

37.

Tsai HJ, Hsiao CF, Chang JS, Chen LT, Chao YJ, Yen CJ, et al. The prognostic and predictive role of chromogranin A in gastroenteropancreatic neuroendocrine tumors - a single-center experience. Front Oncol. 2021;11: 741096. https://doi.org/10.3389/fonc.2021.741096.CrossRefPubMedPubMedCentral

38.

Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011;96(12):3741–9. https://doi.org/10.1210/jc.2011-0666.CrossRefPubMed

39.

Pavel ME, Baudin E, Öberg KE, Hainsworth JD, Voi M, Rouyrre N, et al. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Ann Oncol. 2017;28(7):1569–75. https://doi.org/10.1093/annonc/mdx193.CrossRefPubMedPubMedCentral

40.

Yao JC, Pavel M, Lombard-Bohas C, Van Cutsem E, Voi M, Brandt U, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study. J Clin Oncol. 2016;34(32):3906–13. https://doi.org/10.1200/jco.2016.68.0702.CrossRefPubMedPubMedCentral

41.

Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28(1):69–76. https://doi.org/10.1200/jco.2009.24.2669.CrossRefPubMed

42.

Jensen KH, Hilsted L, Jensen C, Mynster T, Rehfeld JF, Knigge U. Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors. Scand J Gastroenterol. 2013;48(1):70–7. https://doi.org/10.3109/00365521.2012.733953.CrossRefPubMed

43.

Chou WC, Chen JS, Hung YS, Hsu JT, Chen TC, Sun CF, et al. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors. Anticancer Res. 2014;34(10):5661–9.PubMed

44.

Huizing DMV, Aalbersberg EA, Versleijen MWJ, Tesselaar MET, Walraven I, Lahaye MJ, et al. Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy. Cancer Imaging. 2020;20(1):57. https://doi.org/10.1186/s40644-020-00335-w.CrossRefPubMedPubMedCentral

45.

Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, et al. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. Eur J Nucl Med Mol Imaging. 2020;47(4):895–906. https://doi.org/10.1007/s00259-019-04601-3.CrossRefPubMed

46.

Chan DL, Clarke SJ, Diakos CI, Roach PJ, Bailey DL, Singh S, et al. Prognostic and predictive biomarkers in neuroendocrine tumours. Crit Rev Oncol Hematol. 2017;113:268–82. https://doi.org/10.1016/j.critrevonc.2017.03.017.CrossRefPubMed

47.

Komarnicki P, Musiałkiewicz J, Stańska A, Maciejewski A, Gut P, Mastorakos G, et al. Circulating neuroendocrine tumor biomarkers: past, present and future. J Clin Med. 2022;11(19). https://doi.org/10.3390/jcm11195542.

48.

Monaghan PJ, Lamarca A, Valle JW, Hubner RA, Mansoor W, Trainer PJ, et al. Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours. Clin Endocrinol. 2016;84(3):348–52. https://doi.org/10.1111/cen.12985.CrossRef

49.

Strosberg D, Schneider EB, Onesti J, Saunders N, Konda B, Shah M, et al. Prognostic impact of serum pancreastatin following chemoembolization for neuroendocrine tumors. Ann Surg Oncol. 2018;25(12):3613–20. https://doi.org/10.1245/s10434-018-6741-x.CrossRefPubMed

50.

Sherman SK, Maxwell JE, O’Dorisio MS, O’Dorisio TM, Howe JR. Pancreastatin predicts survival in neuroendocrine tumors. Ann Surg Oncol. 2014;21(9):2971–80. https://doi.org/10.1245/s10434-014-3728-0.CrossRefPubMedPubMedCentral

51.

Tran CG, Sherman SK, Scott AT, Ear PH, Chandrasekharan C, Bellizzi AM, et al. It is time to rethink biomarkers for surveillance of small bowel neuroendocrine tumors. Ann Surg Oncol. 2021;28(2):732–41. https://doi.org/10.1245/s10434-020-08784-0.CrossRefPubMed

52.

Rustagi S, Warner RR, Divino CM. Serum pancreastatin: the next predictive neuroendocrine tumor marker. J Surg Oncol. 2013;108(2):126–8. https://doi.org/10.1002/jso.23359.CrossRefPubMed

53.

Woltering EA, Beyer DT, Thiagarajan R, Ramirez RA, Wang YZ, Ricks MJ, et al. Elevated plasma pancreastatin, but not chromogranin A, predicts survival in neuroendocrine tumors of the duodenum. J Am College Surg. 2016;222(4):534–42. https://doi.org/10.1016/j.jamcollsurg.2015.12.014.CrossRef

54.

van Adrichem RC, Kamp K, Vandamme T, Peeters M, Feelders RA, de Herder WW. Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors. Ann Oncol. 2016;27(4):746–7. https://doi.org/10.1093/annonc/mdv626.CrossRefPubMed

55.

Ma ZY, Gong YF, Zhuang HK, Zhou ZX, Huang SZ, Zou YP, et al. Pancreatic neuroendocrine tumors: a review of serum biomarkers, staging, and management. World J Gastroenterol. 2020;26(19):2305–22. https://doi.org/10.3748/wjg.v26.i19.2305.CrossRefPubMedPubMedCentral

56.

Sansone A, Lauretta R, Vottari S, Chiefari A, Barnabei A, Romanelli F, et al. Specific and non-specific biomarkers in neuroendocrine gastroenteropancreatic tumors. Cancers. 2019;11(8). https://doi.org/10.3390/cancers11081113.

57.

Bocchini M, Nicolini F, Severi S, Bongiovanni A, Ibrahim T, Simonetti G, et al. Biomarkers for pancreatic neuroendocrine neoplasms (PanNENs) management-an updated review. Front Oncol. 2020;10:831. https://doi.org/10.3389/fonc.2020.00831.CrossRefPubMedPubMedCentral

58.

•• Öberg K. Molecular genomic blood biomarkers for neuroendocrine tumors: the long and winding road from Berzelius and Bence Jones to a neuroendocrine destination. Neuroendocrinology. 2021;111(4):297–303. https://doi.org/10.1159/000508488. This review summarizes the evolution and progress in the development of biomarkers in NENs.CrossRefPubMed

59.

Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes. 2018;25(1):22–35. https://doi.org/10.1097/med.0000000000000376.CrossRefPubMedPubMedCentral

60.

Grozinsky-Glasberg S, Davar J, Hofland J, Dobson R, Prasad V, Pascher A, et al. European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease. J Neuroendocrinol. 2022;34(7): e13146. https://doi.org/10.1111/jne.13146.CrossRefPubMedPubMedCentral

61.

Meijer WG, Kema IP, Volmer M, Willemse PH, de Vries EG. Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem. 2000;46(10):1588–96.CrossRefPubMed

62.

Wedin M, Mehta S, Angerås-Kraftling J, Wallin G, Daskalakis K. The role of serum 5-HIAA as a predictor of progression and an alternative to 24-h urine 5-HIAA in well-differentiated neuroendocrine neoplasms. Biology. 2021;10(2). https://doi.org/10.3390/biology10020076.

63.

Tellez MR, Mamikunian G, O’Dorisio TM, Vinik AI, Woltering EA. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs). Pancreas. 2013;42(3):405–10. https://doi.org/10.1097/MPA.0b013e318271c0d5.CrossRefPubMed

64.

Adaway JE, Dobson R, Walsh J, Cuthbertson DJ, Monaghan PJ, Trainer PJ, et al. Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement. Ann Clin Biochem. 2016;53(Pt 5):554–60. https://doi.org/10.1177/0004563215613109.CrossRefPubMed

65.

Zandee WT, Kamp K, van Adrichem RC, Feelders RA, de Herder WW. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours. Eur J Endocrinol. 2016;175(5):361–6. https://doi.org/10.1530/eje-16-0392.CrossRefPubMed

66.

Bhattacharyya S, Toumpanakis C, Chilkunda D, Caplin ME, Davar J. Risk factors for the development and progression of carcinoid heart disease. Am J Cardiol. 2011;107(8):1221–6. https://doi.org/10.1016/j.amjcard.2010.12.025.CrossRefPubMed

67.

Giannis D, Moris D, Karachaliou GS, Tsilimigras DI, Karaolanis G, Papalampros A, et al. Insulinomas: from diagnosis to treatment. A review of the literature. J BUON. 2020;25(3):1302-14.

68.

•• Hofland J, Falconi M, Christ E, Castaño JP, Faggiano A, Lamarca A, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. Journal of neuroendocrinology. 2023;35(8):e13318. https://doi.org/10.1111/jne.13318. This 2023 ENETs paper provides a practical guide for clinicians to diagnose, treat, and monitor F-NENs.

69.

Song X, Zheng S, Yang G, Xiong G, Cao Z, Feng M, et al. Glucagonoma and the glucagonoma syndrome. Oncol Lett. 2018;15(3):2749–55. https://doi.org/10.3892/ol.2017.7703.CrossRefPubMed

70.

de Herder WW, Hofland J. Somatostatinoma. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc. Copyright © 2000-2023, MDText.com, Inc.; 2000.

71.

Elangovan A, Zulfiqar H. Somatostatinoma. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Hassam Zulfiqar declares no relevant financial relationships with ineligible companies.: StatPearls Publishing. Copyright © 2023, StatPearls Publishing LLC.; 2023.

72.

Bloom SR. Vasoactive intestinal peptide, the major mediator of the WDHA (pancreatic cholera) syndrome: value of measurement in diagnosis and treatment. Am J Digest Dis. 1978;23(4):373–6. https://doi.org/10.1007/bf01072425.CrossRefPubMed

73.

Melone V, Salvati A, Palumbo D, Giurato G, Nassa G, Rizzo F, et al. Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis. J Transl Med. 2022;20(1):306. https://doi.org/10.1186/s12967-022-03511-7.CrossRefPubMedPubMedCentral

74.

Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65–71. https://doi.org/10.1038/nature21063.CrossRefPubMed

75.

• Korotaeva A, Mansorunov D, Apanovich N, Kuzevanova A, Karpukhin A. MiRNA expression in neuroendocrine neoplasms of frequent localizations. Non-coding RNA. 2021;7(3). https://doi.org/10.3390/ncrna7030038. This review gives an extensive overview of the hitherto known miRNAs and their functional characteristics in different types of NENs.

76.

Malczewska A, Kidd M, Matar S, Kos-Kudla B, Modlin IM. A comprehensive assessment of the role of miRNAs as biomarkers in gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology. 2018;107(1):73–90. https://doi.org/10.1159/000487326.CrossRefPubMed

77.

Bowden M, Zhou CW, Zhang S, Brais L, Rossi A, Naudin L, et al. Profiling of metastatic small intestine neuroendocrine tumors reveals characteristic miRNAs detectable in plasma. Oncotarget. 2017;8(33):54331–44. https://doi.org/10.18632/oncotarget.16908.CrossRefPubMedPubMedCentral

78.

Malczewska A, Frampton AE, Mato Prado M, Ameri S, Dabrowska AF, Zagorac S, et al. Circulating microRNAs in small-bowel neuroendocrine tumors: a potential tool for diagnosis and assessment of effectiveness of surgical resection. Ann Surg. 2021;274(1):e1–9. https://doi.org/10.1097/sla.0000000000003502.CrossRefPubMed

79.

Kövesdi A, Kurucz PA, Nyírő G, Darvasi O, Patócs A, Butz H. Circulating miRNA increases the diagnostic accuracy of chromogranin A in metastatic pancreatic neuroendocrine tumors. Cancers. 2020;12(9). https://doi.org/10.3390/cancers12092488.

80.

Özdirik B, Stueven AK, Mohr R, Geisler L, Wree A, Knorr J, et al. Analysis of miR-29 serum levels in patients with neuroendocrine tumors-results from an exploratory study. Journal of clinical medicine. 2020;9(9). https://doi.org/10.3390/jcm9092881.

81.

Arvidsson Y, Rehammar A, Bergström A, Andersson E, Altiparmak G, Swärd C, et al. miRNA profiling of small intestinal neuroendocrine tumors defines novel molecular subtypes and identifies miR-375 as a biomarker of patient survival. Mod Pathol: an official journal of the United States and Canadian Academy of Pathology, Inc. 2018;31(8):1302-17. https://doi.org/10.1038/s41379-018-0010-1.

82.

Bocchini M, Tazzari M, Ravaioli S, Piccinini F, Foca F, Tebaldi M, et al. Circulating hsa-miR-5096 predicts (18)F-FDG PET/CT positivity and modulates somatostatin receptor 2 expression: a novel miR-based assay for pancreatic neuroendocrine tumors. Front Oncol. 2023;13:1136331. https://doi.org/10.3389/fonc.2023.1136331.CrossRefPubMedPubMedCentral

83.

Modlin IM, Drozdov I, Kidd M. The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PloS One. 2013;8(5): e63364. https://doi.org/10.1371/journal.pone.0063364.CrossRefPubMedPubMedCentral

84.

Modlin IM, Drozdov I, Alaimo D, Callahan S, Teixiera N, Bodei L, et al. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection. Endocr Relat Cancer. 2014;21(4):615–28. https://doi.org/10.1530/erc-14-0190.CrossRefPubMed

85.

Malczewska A, Oberg K, Kos-Kudla B. NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis. Endocr Connect. 2021;10(1):110–23. https://doi.org/10.1530/ec-20-0417.CrossRefPubMed

86.

Malczewska A, Witkowska M, Makulik K, Bocian A, Walter A, Pilch-Kowalczyk J, et al. NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging. Endocr Connect. 2019;8(4):442–53. https://doi.org/10.1530/ec-19-0030.CrossRefPubMedPubMedCentral

87.

Malczewska A, Bodei L, Kidd M, Modlin IM. Blood mRNA measurement (NETest) for neuroendocrine tumor diagnosis of image-negative liver metastatic disease. J Clin Endocrinol Metab. 2019;104(3):867–72. https://doi.org/10.1210/jc.2018-01804.CrossRefPubMed

88.

Puliani G, Di Vito V, Feola T, Sesti F, Centello R, Pandozzi C, et al. NETest: a systematic review focusing on the prognostic and predictive role. Neuroendocrinology. 2022;112(6):523–36. https://doi.org/10.1159/000518873.CrossRefPubMed

89.

van Treijen MJC, Korse CM, Verbeek WH, Tesselaar MET, Valk GD. NETest: serial liquid biopsies in gastroenteropancreatic NET surveillance. Endocr Connect. 2022;11(10). https://doi.org/10.1530/ec-22-0146.

90.

Liu E, Paulson S, Gulati A, Freudman J, Grosh W, Kafer S, et al. Assessment of NETest clinical utility in a U.S. registry-based study. Oncologist. 2019;24(6):783–90. https://doi.org/10.1634/theoncologist.2017-0623.CrossRefPubMed

91.

Ćwikła JB, Bodei L, Kolasinska-Ćwikła A, Sankowski A, Modlin IM, Kidd M. Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy. J Clin Endocrinol Metab. 2015;100(11):E1437-45. https://doi.org/10.1210/jc.2015-2792.CrossRefPubMed

92.

Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, et al. PRRT genomic signature in blood for prediction of (177)Lu-octreotate efficacy. Eur J Nucl Med Mol Imaging. 2018;45(7):1155–69. https://doi.org/10.1007/s00259-018-3967-6.CrossRefPubMedPubMedCentral

93.

Modlin IM, Frilling A, Salem RR, Alaimo D, Drymousis P, Wasan HS, et al. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies. Surgery. 2016;159(1):336–47. https://doi.org/10.1016/j.surg.2015.06.056.CrossRefPubMed

94.

Filosso PL, Kidd M, Roffinella M, Lewczuk A, Chung KM, Kolasinska-Cwikla A, et al. The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression. Eur J Cardio-thoracic Surg. 2018;53(3):631–9. https://doi.org/10.1093/ejcts/ezx386.CrossRef

95.

• Modlin IM, Kidd M, Falconi M, Filosso PL, Frilling A, Malczewska A, et al. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility. Ann Oncol. 2021;32(11):1425–33. https://doi.org/10.1016/j.annonc.2021.08.1746. This article shows in an extensive, international cohort that the NETest is more accurate to diagnose, grade, identify metastases, and predict recurrence as compared to CgA.CrossRefPubMed

96.

Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, et al. Circulating tumor cells: biology and clinical significance. Sig Transduct Target Ther. 2021;6(1):404. https://doi.org/10.1038/s41392-021-00817-8.CrossRef

97.

Khan MS, Tsigani T, Rashid M, Rabouhans JS, Yu D, Luong TV, et al. Circulating tumor cells and EpCAM expression in neuroendocrine tumors. Clin Cancer Res. 2011;17(2):337–45. https://doi.org/10.1158/1078-0432.ccr-10-1776.CrossRefPubMed

98.

Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME, et al. Circulating tumor cells as prognostic markers in neuroendocrine tumors. J Clin Oncol. 2013;31(3):365–72. https://doi.org/10.1200/jco.2012.44.2905.CrossRefPubMed

99.

Ehlers M, Allelein S, Haase M, Willenberg HS, Knoefel WT, Schott M. Circulating tumor cells in patients with neuroendocrine neoplasms. Horm. Metab. Res. = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2014;46(10):744-5. https://doi.org/10.1055/s-0034-1383649.

100.

Rizzo FM, Vesely C, Childs A, Marafioti T, Khan MS, Mandair D, et al. Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours. Br J Cancer. 2019;120(3):294–300. https://doi.org/10.1038/s41416-018-0367-4.CrossRefPubMedPubMedCentral

101.

Khan MS, Kirkwood AA, Tsigani T, Lowe H, Goldstein R, Hartley JA, et al. Early changes in circulating tumor cells are associated with response and survival following treatment of metastatic neuroendocrine neoplasms. Clin Cancer Res. 2016;22(1):79–85. https://doi.org/10.1158/1078-0432.ccr-15-1008.CrossRefPubMed

102.

Grande E, Capdevila J, Castellano D, Teulé A, Durán I, Fuster J, et al. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Ann Oncol. 2015;26(9):1987–93. https://doi.org/10.1093/annonc/mdv252.CrossRefPubMed

103.

Meyer T, Caplin M, Khan MS, Toumpanakis C, Shetty S, Ramage JK, et al. Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours. J Neuroendocrinol. 2022;34(4): e13096. https://doi.org/10.1111/jne.13096.CrossRefPubMedPubMedCentral

104.

Childs A, Vesely C, Ensell L, Lowe H, Luong TV, Caplin ME, et al. Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours. Br J Cancer. 2016;115(12):1540–7. https://doi.org/10.1038/bjc.2016.377.CrossRefPubMedPubMedCentral

105.

Childs A, Steele CD, Vesely C, Rizzo FM, Ensell L, Lowe H, et al. Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms. Endocr Relat Cancer. 2021;28(9):631–44. https://doi.org/10.1530/erc-21-0179.CrossRefPubMedPubMedCentral

106.

Boons G, Vandamme T, Peeters M, Beyens M, Driessen A, Janssens K, et al. Cell-free DNA from metastatic pancreatic neuroendocrine tumor patients contains tumor-specific mutations and copy number variations. Front Oncol. 2018;8:467. https://doi.org/10.3389/fonc.2018.00467.CrossRefPubMedPubMedCentral

107.

Zakka K, Nagy R, Drusbosky L, Akce M, Wu C, Alese OB, et al. Blood-based next-generation sequencing analysis of neuroendocrine neoplasms. Oncotarget. 2020;11(19):1749–57. https://doi.org/10.18632/oncotarget.27588.CrossRefPubMedPubMedCentral

108.

Knappskog S, Grob T, Venizelos A, Amstutz U, Hjortland GO, Lothe IM, et al. Mutation spectrum in liquid versus solid biopsies from patients with advanced gastroenteropancreatic neuroendocrine carcinoma. JCO Precis Oncol=. 2023;7: e2200336. https://doi.org/10.1200/po.22.00336.CrossRefPubMedPubMedCentral

109.

Boons G, Vandamme T, Ibrahim J, Roeyen G, Driessen A, Peeters D, et al. PDX1 DNA methylation distinguishes two subtypes of pancreatic neuroendocrine neoplasms with a different prognosis. Cancers. 2020;12(6). https://doi.org/10.3390/cancers12061461.

110.

Di Domenico A, Pipinikas CP, Maire RS, Bräutigam K, Simillion C, Dettmer MS, et al. Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression. Commun Biol. 2020;3(1):740. https://doi.org/10.1038/s42003-020-01479-y.CrossRefPubMedPubMedCentral

111.

• Mettler E, Fottner C, Bakhshandeh N, Trenkler A, Kuchen R, Weber MM. Quantitative analysis of plasma cell-free DNA and its DNA integrity and hypomethylation status as biomarkers for tumor burden and disease progression in patients with metastatic neuroendocrine neoplasias. Cancers. 2022;14(4). https://doi.org/10.3390/cancers14041025. Research article that demonstrates how the combination of high cfDNA concentrations decreases in DNA integrity and global hypomethylation can be used as a marker for disease burden and worse prognosis in metastatic NEN patients.

Title: The Quest for Circulating Biomarkers in Neuroendocrine Neoplasms: a Clinical Perspective
Authors: Laura Mariën, MSc
Odeta Islam, MD
Siddharth Chhajlani, MD
Willem Lybaert, MD
Marc Peeters, MD, PhD
Guy Van Camp, PhD
Ken Op de Beeck, PhD
Timon Vandamme, MD, PhD
Publication date: 22-11-2023
Publisher: Springer US
Keywords: Neuroendocrine Tumor
Biomarkers
Endocrinology
Gastroenterology
Published in: Current Treatment Options in Oncology / Issue 12/2023
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-023-01147-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Opinion statement

Please log in to get access to this content

Other articles of this Issue 12/2023

Nonsurgical therapeutic strategies for nonmelanoma skin cancers

The Evolving Treatment Landscape of Medullary Thyroid Cancer

Selecting Optimal First-Line Treatment for Microsatellite Stable and Non-Mutated RAS/BRAF Metastatic Colorectal Cancer

Treatment of non-small-cell lung cancer with atypical EGFR mutations

Treatment of melanoma brain and leptomeningeal metastases

Update of Diagnosis and Targeted Therapy for ALK+ Inflammation Myofibroblastic Tumor

Keynote webinar | Spotlight on antibody–drug conjugates in cancer